Author

Qingru Xu

Dana-Farber Cancer InstituteORCID 0009-0009-4372-2496Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Qingru Xu1 paper · Yale University

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1 Approach:statistical model· 1

Frequent Co-Authors

Ananthan SadagopaniD· 2 shared Bingchen LiiD· 2 shared Jiao LiiD· 2 shared Prateek KhannaiD· 2 shared Toni K. ChoueiriiD· 2 shared Birgitta A. RybackiD· 1 shared Cary N. WeissiD· 1 shared Chin‐Lee WuiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ananthan SadagopanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 11, 2025

Dual Inhibition of CDK4/6 and mTORC1 Establishes a Preclinical Strategy for Translocation Renal Cell Carcinoma

Shikha Gupta, Prateek Khanna, Eddy Saad…·Srinivas R. Viswanathan

This study identifies CDK4/6 and mTORC1 pathway activation in tRCC and shows that their dual inhibition synergistically suppresses tRCC cell growth in vitro and xenografts in vivo.

DOI 10.1101/2025.07.11.663903

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyNature MetabolismPeer-reviewedFeb 6, 2025

TFE3 fusions direct an oncogenic transcriptional program that drives OXPHOS and unveils vulnerabilities in translocation renal cell carcinoma

Jiao Li, Kaimeng Huang, Meha Thakur…·Srinivas Raghavan Viswanathan

This study identifies TFE3 fusions driving OXPHOS in tRCC and reveals EGLN1 inhibition as a therapeutic target.

29 citationstop 1%

humanbulk RNA-seq

𝕏 PostBluesky